AUSTIN, Texas, April 14, 2016 /PRNewswire/ -- Luminex
Corporation (NASDAQ: LMNX) today announced that its SYNCT™ Software
has received both U.S. Food and Drug Administration (FDA) clearance
and CE Marking for use with its ARIES® System and
NxTAG® assays on the MAGPIX® System. SYNCT
Software is middleware that provides access to data and reports
through a single interface, and allows for customizable workflows
by connecting ARIES® and NxTAG-enabled MAGPIX
workstations in the lab.
![Luminex logo. (PRNewsFoto/LUMINEX CORP.) Luminex logo. (PRNewsFoto/LUMINEX CORP.)](https://photos.prnewswire.com/prnvar/20150201/172702LOGO)
Specifically designed for molecular laboratories running
ARIES® and NxTAG assays, SYNCT empowers laboratory
directors by offering a streamlined workflow, enhanced data
management, and the ability to easily add new functionality. From
anywhere in the lab, users can create and prepare orders or manage
results from all next-generation Luminex instruments, allowing for
division of labor and flexibility to work within any lab process
connected to SYNCT. Centralized reporting allows for higher-quality
results because data can be accumulated in one place and overseen
by the laboratory director. Labs with multiple locations can use
SYNCT Software to route all results to a single reviewer, anywhere
on the lab network, before sending to the lab information
system.
"SYNCT is efficient software for our daily workflow," said Tong
Her, Medical Laboratory Scientist, Test Development and Validation,
St. John Hospital and Medical Center. "The order management menu
makes it easy to order tests and the 'run report' tool allows for
simple interpretation of test results."
Optional applications that provide more functionality and value
can easily be added with minimal validation effort. As an example,
the ARIES® UDP (User Defined Protocol) App enables
customers to create assay protocol files for running analyte
specific reagents or customer developed primers in laboratory
developed tests.
"Challenges associated with software and information systems
that don't talk to each other waste precious time that lab
directors would rather spend maximizing efficiency and ensuring the
most accurate and reproducible results from their lab," said
Eric Shapiro, Vice President, Global
Marketing at Luminex Corporation. "We are proud to offer our
molecular lab customers a better way to manage their data while
reducing operational costs."
About the ARIES® System
The
ARIES® System is a sample to answer molecular
diagnostic system designed to increase laboratory efficiency,
ensure result accuracy, and fit seamlessly into today's lean
laboratory environment. ARIES® uses internal
barcode scanning and other advanced features to minimize operator
errors. Two independent modules each support from one to six
cassettes, allowing for both STAT and Batch testing of IVD and
homebrew assays using MultiCode® Reagents when using a
common Universal Assay Protocol. An integrated touchscreen PC
eliminates the need for a separate computer, standalone keyboard,
and mouse, maximizing valuable bench space. Learn more about
connecting the ARIES® System to your LIS.
About NxTAG
NxTAG Respiratory Pathogen
Panel is CE-marked in Europe, and FDA-cleared in
the U.S. NxTAG Respiratory Pathogen Panel is an assay
that detects relevant viral and bacterial respiratory pathogens,
including the atypical bacteria Chlamydophila
pneumoniae and Mycoplasma pneumoniae. The panel is
the only respiratory assay that enables laboratories to easily and
simultaneously detect these respiratory pathogens in a single,
closed tube system and in a format that scales to accommodate
changes in throughput needed to respond to seasonal changes in
demand, especially during flu season. NxTAG Respiratory
Pathogen Panel requires only minutes of hands-on time with no
upstream reagent preparation. The innovative tube strip design
offers laboratories the flexibility to process a single sample or
up to 96 samples per run, without wasting consumables or reagents.
Total turnaround time is only about three hours for 96 samples
(excluding extraction).
About Luminex Corporation
Luminex is committed to
applying its passion for innovation toward creating breakthrough
solutions to improve health and advance science. The company is
transforming global healthcare and life-science research through
the development, manufacturing and marketing of proprietary
instruments and assays utilizing xMAP® open-architecture
multi-analyte platform, MultiCode® real-time polymerase chain
reaction (PCR), and multiplex PCR-based technologies, that deliver
cost-effective rapid results to clinicians and researchers.
Luminex's technology is commercially available worldwide and in use
in leading clinical laboratories, as well as major pharmaceutical,
diagnostic, biotechnology and life science companies. Luminex is
meeting the needs of customers in markets as diverse as clinical
diagnostics, pharmaceutical drug discovery, biomedical research
including genomic and proteomic research, personalized medicine,
biodefense research and food safety. For further information on
Luminex Corporation and the latest advances in multiplexing using
award-winning technology, please visit
http://www.luminexcorp.com/.
Statements made in this release that express Luminex's or
management's intentions, plans, beliefs, expectations or
predictions of future events are forward-looking statements.
Forward-looking statements in this release include statements
regarding the development and testing progress of our pipeline
products, and the regulatory approvals thereof. The words
"believe", "expect", "intend", "anticipates", "confident", "will",
"could", "should", and similar expressions are intended to
further identify such forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995. It is
important to note that the Company's actual results or performance
could differ materially from those anticipated in such
forward-looking statements. Factors that could cause Luminex's
actual results or performance to differ materially include risks
and uncertainties relating to, among others, our ability to launch
products on time, the timing of regulatory approvals, the outcome
of clinical trials as well as the risks discussed under the heading
"Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as
filed with the Securities and Exchange Commission. The forward
looking statements contained herein represent the judgment of
Luminex as of the date of this press release, and Luminex expressly
disclaims any intent, obligation or undertaking to release publicly
any updates or revisions to any forward-looking statements to
reflect any change in Luminex's expectations with regard thereto or
any change in events, conditions or circumstances on which any such
statements are based.
Contacts
Luminex Investor
Contact
Harriss Currie
Sr. Vice President of Finance and CFO
512.219.8020
hcurrie@luminexcorp.com
Luminex Media Contact
Christine Valle
Sr. Manager, Global Marketing
512.219.8020
cvalle@luminexcorp.com
Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/luminex-corporation-receives-fda-clearance-and-ce-mark-for-synct-software-300251320.html
SOURCE Luminex Corporation